Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial

Journal of Crohn's & Colitis
D T RubinUlcerative Colitis Remission Study Group

Abstract

This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine. In this phase 3b/4, open-label, multicentre, prospective, single-arm study, patients with mild-to-moderate ulcerative colitis were treated with multimatrix mesalazine 4.8g/day once daily for 8 weeks [induction phase]. At Week 8, those who achieved complete or partial remission, based on predefined clinical and endoscopic criteria, were eligible to receive 12 months of multimatrix mesalazine 2.4g/day once daily maintenance therapy. The primary endpoint was the proportion of patients in complete remission at Month 12. A total of 717 patients received induction treatment; 25.9% and 39.3% of patients achieved complete and partial remission, respectively, at Week 8. A total of 461 patients entered the maintenance phase. The likelihood of remaining in/achieving complete remission at Month 12 was higher for patients who entered the maintenance phase in complete remission compared with those who began maintenance in partial remission [47.8% vs 26.0%; p < 0.001]. At Month 12, mucosal healing [endoscopy score ≤ 1] was demonstrated in 7...Continue Reading

References

Feb 17, 2006·Alimentary Pharmacology & Therapeutics·S V Kane
Jan 20, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Gary R LichtensteinWilliam J Sandborn
Jan 24, 2007·Gastroenterology·Michael A KammRaymond E Joseph
Nov 2, 2007·Inflammatory Bowel Diseases·E Jan Irvine
Aug 2, 2008·Inflammatory Bowel Diseases·Michael A KammRaymond Joseph
Jan 14, 2010·The American Journal of Gastroenterology·Asher KornbluthUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Mar 1, 2008·Journal of Crohn's & Colitis·S P L TravisUNKNOWN European Crohn's and Colitis Organisation (ECCO)
May 3, 2011·Gastroenterology·Jacques CosnesAntoine Cortot
May 9, 2012·The American Journal of Gastroenterology·Geert D'HaensPaul Streck
May 4, 2013·Expert Review of Gastroenterology & Hepatology·Makoto NaganumaToshifumi Hibi
Jul 30, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Fuminao TakeshimaKazuhiko Nakao

❮ Previous
Next ❯

Citations

Sep 17, 2016·Gastrointestinal Endoscopy Clinics of North America·Deepa T PatilRobert D Odze
Dec 19, 2019·Expert Opinion on Biological Therapy·Arianna Dal BuonoSilvio Danese
Mar 18, 2020·Journal of Crohn's & Colitis·Stefan SchreiberKaren Barrett
Sep 29, 2018·Inflammatory Bowel Diseases·Tomohiro FukudaTakanori Kanai
Jan 13, 2017·Drugs·Pedro Boal Carvalho, José Cotter
Dec 28, 2016·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·Alicia AlgabaFernando Bermejo
Aug 18, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Toer W StevensGeert R D'Haens
Mar 3, 2021·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Aaron YarlasArpita Nag
Jul 29, 2020·Current Drug Targets·Arianna Dal BuonoSilvio Danese

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy

Clinical Trials Mentioned

NCT01124149

Software Mentioned

SAS
FoTA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.